当前位置： SCI文献检索 > Clinical Genitourinary Cancer期刊下所有文献 > Phase II trial of sunitinib for the therapy of progressive metastatic castration-refractory prostate cancer after previous docetaxel chemotherapy.

Phase II trial of sunitinib for the therapy of progressive metastatic castration-refractory prostate cancer after previous docetaxel chemotherapy.

Abstract：

:Effective options are lacking for progressive castration-refractory prostate cancer (CRPC) after conventional chemotherapy. Sunitinib is an orally administered multitargeted tyrosine kinase inhibitor that is approved multinationally for renal cell carcinoma and gastrointestinal stromal tumors. A phase II trial was conducted to examine the efficacy and toxicities of sunitinib in metastatic CRPC progressing after 1-2 previous chemotherapy regimens including docetaxel. The primary objective was clinical progression-free survival (PFS) with a 12-week PFS > or = 30% assumed to be of interest. Secondary objectives included prostate-specific antigen (PSA) response, modulation of PSA kinetics, objective response, quality of life, pain, survival, and toxicities. Sunitinib 50 mg daily was administered orally on days 1-28 of each 6-week cycle. Patients were treated to a maximum of 8 cycles or until clinically progressive disease or intolerable toxicity.

journal_name

Clin Genitourin Cancer

journal_title

Clinical genitourinary cancer

authors

Sonpavde G,Hutson TE,Berry WR,Boehm KA,Asmar L

doi

10.3816/CGC.2008.n.023

subject

Has Abstract

pub_date

2008-09-01 00:00:00

pages

134-7

issue

2

eissn

1558-7673

issn

1938-0682

pii

S1558-7673(11)70070-2

journal_volume

6

pub_type

杂志文章,多中心研究

相关文献

Clinical Genitourinary Cancer文献大全
  • Standard vs adapted sunitinib regimen in elderly patients with metastatic renal cell cancer: results from a large retrospective analysis.

    abstract：BACKGROUND:There are no data on the patterns of care and outcome of elderly patients with mRCC treated with sunitinib. In a retrospective study, we assessed the routine use of first-line sunitinib in mRCC patients aged ≥ 70 years. PATIENTS AND METHODS:We reviewed the clinical files of 185 patients aged ≥ 70 years with...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2013.11.005

    authors： De Giorgi U,Scarpi E,Sacco C,Aieta M,Lo Re G,Sava T,Masini C,De Vincenzo F,Baldazzi V,Camerini A,Fornarini G,Burattini L,Rosti G,Ferrari V,Moscetti L,Chiuri VE,Luzi Fedeli S,Amadori D,Basso U

    更新日期：2014-06-01 00:00:00

  • Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma.

    abstract：PURPOSE:Similar to other molecularly targeted agents, temsirolimus, an inhibitor of mammalian target of rapamycin, has shown promising activity in advanced renal cell carcinoma. However, only a subset of patients appears to derive significant tumor responses. In an effort to identify potential predictors of response to...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.3816/CGC.2007.n.020

    authors： Cho D,Signoretti S,Dabora S,Regan M,Seeley A,Mariotti M,Youmans A,Polivy A,Mandato L,McDermott D,Stanbridge E,Atkins M

    更新日期：2007-09-01 00:00:00

  • Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 Study.

    abstract：BACKGROUND:Patients with biochemically recurrent prostate cancer and short prostate-specific antigen doubling time (PSADT) are at risk for metastasis yet may wish to avoid androgen deprivation therapy. Itraconazole may have antitumor activity without affecting circulating androgen levels. We therefore evaluated itracon...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2018.09.013

    authors： Lee M,Hong H,Kim W,Zhang L,Friedlander TW,Fong L,Lin AM,Small EJ,Wei XX,Rodvelt TJ,Miralda B,Stocksdale B,Ryan CJ,Aggarwal R

    更新日期：2019-02-01 00:00:00

  • Pathologic Predictors of Survival During Lymph Node Dissection for Metastatic Renal-Cell Carcinoma: Results From a Multicenter Collaboration.

    abstract：PURPOSE:To determine the therapeutic value of lymph node dissection (LND) during cytoreductive nephrectomy (CN) and assess predictors of cancer-specific survival (CSS) in metastatic renal-cell carcinoma. PATIENTS AND METHODS:We identified 293 consecutive patients treated with CN at 4 academic institutions from March 2...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.clgc.2017.10.004

    authors： Chipollini J,Abel EJ,Peyton CC,Boulware DC,Karam JA,Margulis V,Master VA,Zargar-Shoshtari K,Matin SF,Sexton WJ,Raman JD,Wood CG,Spiess PE

    更新日期：2018-04-01 00:00:00

  • Gynecologic Organ Involvement During Radical Cystectomy for Bladder Cancer: Is It Time to Routinely Spare the Ovaries?

    abstract：PURPOSE:To determine a subset of women who could undergo ovary-sparing radical cystectomy (OSRC) for bladder cancer without compromising oncologic safety. PATIENTS AND METHODS:A retrospective review was performed of 164 consecutive women who underwent cystectomy at a single tertiary-care center from 1997 to 2018. Clin...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2018.10.009

    authors： Taylor BL,Matrai CE,Smith AL,Ayangbesan A,Xia L,Golombos DM,Mosquera JM,Nicolas J,Robinson BD,Scherr DS,Khani F

    更新日期：2019-02-01 00:00:00

  • Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced Prostate Cancer? A Meta-analysis.

    abstract：BACKGROUND:Results from large randomized controlled trials combining docetaxel, abiraterone, celecoxib, or bisphosphonates with androgen deprivation therapy (ADT) in hormone-sensitive prostate cancer have emerged. However, in our knowledge, few data are available in patients older than 70 years. Therefore, we undertook...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,meta分析

    doi：10.1016/j.clgc.2019.05.001

    authors： Landre T,Guetz GD,Chouahnia K,Fossey-Diaz V,Taleb C,Culine S

    更新日期：2019-08-01 00:00:00

  • Contemporary Incidence and Mortality Rates in Patients With Testicular Germ Cell Tumors.

    abstract：BACKGROUND:We comprehensively tested contemporary incidence and mortality rates in patients with germ cell tumor of the testis (GCTT). MATERIALS AND METHODS:Within the Surveillance, Epidemiology, and End Results database (2004-2015), statistical analyses included estimated annual percentage changes, multivariable logi...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2019.06.003

    authors： Palumbo C,Mistretta FA,Mazzone E,Knipper S,Tian Z,Perrotte P,Antonelli A,Montorsi F,Shariat SF,Saad F,Simeone C,Briganti A,Lattouf JB,Karakiewicz PI

    更新日期：2019-10-01 00:00:00

  • Which Factors Predict Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Post-Docetaxel?

    abstract：BACKGROUND:Abiraterone acetate (AA) increases overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel. However, survival time varies substantially between individuals. Our goal was to identify prognostic factors that better estimate OS. MATERIALS...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.clgc.2017.01.019

    authors： Van Praet C,Rottey S,Van Hende F,Pelgrims G,Demey W,Van Aelst F,Wynendaele W,Gil T,Schatteman P,Filleul B,Schallier D,Machiels JP,Schrijvers D,Everaert E,D'Hondt L,Werbrouck P,Vermeij J,Mebis J,Clausse M,Rasschaert

    更新日期：2017-08-01 00:00:00

  • Sociodemographic Disparities in the Nonoperative Management of Small Renal Masses.

    abstract：BACKGROUND:Local tumor ablation (LTA) and expectant management (EM) represent competing treatment modalities for patients with small renal masses (SRMs) who are unfit for surgery. We examined the potential social discrepancies in the access of LTA and EM. MATERIALS AND METHODS:A total of 1860 patients with cT1a kidney...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2015.10.011

    authors： Trudeau V,Larcher A,Sun M,Boehm K,Dell'Oglio P,Meskawi M,Sosa J,Tian Z,Fossati N,Briganti A,Karakiewicz PI

    更新日期：2016-04-01 00:00:00

  • National trends in the recommendation of radiotherapy after prostatectomy for prostate cancer before and after the reporting of a survival benefit in March 2009.

    abstract：BACKGROUND:Three randomized trials demonstrated that postprostatectomy adjuvant radiotherapy improves biochemical disease-free survival for patients with adverse pathologic features, and 1 trial found adjuvant radiotherapy improves overall survival. We sought to determine whether postprostatectomy radiotherapy (PPRT) u...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2014.12.005

    authors： Mahal BA,Hoffman KE,Efstathiou JA,Nguyen PL

    更新日期：2015-06-01 00:00:00

  • Location of Metastases in Contemporary Prostate Cancer Patients Affects Cancer-Specific Mortality.

    abstract：PURPOSE:To quantify the prognostic effect of the location of prostate cancer (PCa) metastases on cancer-specific mortality (CSM) and the rate of other-cause mortality (OCM) in contemporary newly diagnosed metastatic PCa (mPCa) patients. PATIENTS AND METHODS:Within the Surveillance Epidemiology and End Results database...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2018.05.016

    authors： Mazzone E,Preisser F,Nazzani S,Tian Z,Bandini M,Gandaglia G,Fossati N,Soulières D,Graefen M,Montorsi F,Shariat SF,Saad F,Briganti A,Karakiewicz PI

    更新日期：2018-10-01 00:00:00

  • Quantifying the Overall Survival Benefit With Early Radical Cystectomy for Patients With Histologically Confirmed T1 Non-muscle-invasive Bladder Cancer.

    abstract：INTRODUCTION:The objective of this study was to examine the overall survival (OS) in patients diagnosed with high-grade T1 non-muscle-invasive bladder cancer treated with early radical cystectomy versus local treatment of the primary tumor, defined as endoscopic management with or without intravesical chemotherapy or i...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2020.03.013

    authors： Tully KH,Roghmann F,Noldus J,Chen X,Häuser L,Kibel AS,Sonpavde GP,Mossanen M,Trinh QD

    更新日期：2020-12-01 00:00:00

  • Racial and Socioeconomic Disparities in Bladder Cancer Survival: Analysis of the California Cancer Registry.

    abstract：PURPOSE:To examine the California Cancer Registry (CCR) for bladder cancer survival disparities based on race, socioeconomic status (SES), and insurance in California patients. PATIENTS AND METHODS:The CCR was queried for bladder cancer cases in California from 1988 to 2012. The primary outcome was disease-specific su...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2019.05.008

    authors： Sung JM,Martin JW,Jefferson FA,Sidhom DA,Piranviseh K,Huang M,Nguyen N,Chang J,Ziogas A,Anton-Culver H,Youssef RF

    更新日期：2019-10-01 00:00:00

  • The current and emerging role of immunotherapy in prostate cancer.

    abstract：:Recent phase III trial results have demonstrated the effectiveness of sipuleucel-T, a therapeutic cancer vaccine, in the treatment of metastatic prostate cancer. Yet, despite the survival benefit of sipuleucel-T, questions remain about how immunologic agents can be used in the treatment of metastatic prostate cancer. ...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,评审

    doi：10.3816/CGC.2010.n.002

    authors： Madan RA,Gulley JL

    更新日期：2010-12-01 00:00:00

  • Secondary hormonal therapy in men with castration-resistant prostate cancer.

    abstract：BACKGROUND:Androgen receptor (AR) signaling remains important in castration-resistant prostate cancer (CRPC) and sequential responses to hormonal therapies are observed. Little is known about the factors associated with responsiveness to secondary hormone therapy (HT). METHODS:We retrospectively identified patients wi...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2011.06.006

    authors： Nakabayashi M,Werner L,Oh WK,Regan MM,Kantoff PW,Taplin ME

    更新日期：2011-12-01 00:00:00

  • Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma and End-stage Renal Disease at 2 Centers.

    abstract：INTRODUCTION:There is scarce information regarding nivolumab treatment for metastatic renal cell carcinoma (mRCC) in patients with end-stage renal disease (ESRD). This study investigated the safety and efficacy of nivolumab in patients with mRCC and ESRD. MATERIALS AND METHODS:This 2-center retrospective study evaluat...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.clgc.2019.04.004

    authors： Tachibana H,Kondo T,Ishihara H,Takagi T,Tanabe K

    更新日期：2019-08-01 00:00:00

  • Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma.

    abstract：BACKGROUND:There is a lack of molecularly-informed biomarkers for patients with metastatic renal cell carcinoma (RCC). Plasma cell-free DNA (cfDNA) sequencing is a minimally-invasive alternative to tissue for profiling the genome in other cancers but relevance in metastatic RCC remains unclear. MATERIALS AND METHODS:W...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2019.12.018

    authors： Bacon JVW,Annala M,Soleimani M,Lavoie JM,So A,Gleave ME,Fazli L,Wang G,Chi KN,Kollmannsberger CK,Wyatt AW,Nappi L

    更新日期：2020-08-01 00:00:00

  • Small renal masses managed with active surveillance: predictors of tumor growth rate after long-term follow-up.

    abstract：BACKGROUND:The purpose of the study was to evaluate the relationships between the patients' clinical characteristics and the growth pattern of SRMs, and to investigate the predictive factors of tumor growth rates in patients initially managed with AS. MATERIALS AND METHODS:We retrospectively reviewed data from our pro...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2014.08.006

    authors： Schiavina R,Borghesi M,Dababneh H,Bianchi L,Longhi B,Diazzi D,Monti C,La Manna G,Martorana G,Brunocilla E

    更新日期：2015-04-01 00:00:00

  • Eosinophilic rash secondary to temsirolimus.

    abstract：:We present a case of a 73-year-old female with metastatic renal cell carcinoma, clear cell histologic subtype, who developed pruritic rash after 2 weeks of 25 mg weekly infusions of temsirolimus. Rash was located on bilateral antecubital areas and posterior knees. Skin biopsy showed spongiotic dermatitis with eosinoph...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.3816/CGC.2009.n.019

    authors： Gandhi M,Kuzel T,Lacouture M

    更新日期：2009-08-01 00:00:00

  • Darbepoetin alfa administered every 4 weeks for anemia in patients with advanced prostate cancer.

    abstract：PURPOSE:Anemia is a common morbidity of advanced prostate cancer, and prostate cancer treatment and has been associated with a worse overall survival and reduced quality of life in patients with prostate cancer. We sought to determine if infrequent dosing of darbepoetin alfa is safe and effective in treating anemia in ...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.3816/CGC.2007.n.012

    authors： Beer TM,Bergenstock M,Birt K,Higano CS

    更新日期：2007-06-01 00:00:00

  • Associations Between Prostate Volume and Oncologic Outcomes in Men Undergoing Focal Cryoablation of the Prostate.

    abstract：INTRODUCTION:The purpose of this study was to assess the relationship of total prostate volume (TPV) and oncologic outcomes following focal prostate cryoablation. MATERIALS AND METHODS:A query of the Cryo On-Line Database (COLD) registry for men who underwent primary focal prostate cryoablation revealed 829 patients w...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.clgc.2017.10.009

    authors： Elshafei A,Tay KJ,Kara O,Malkoc E,Nyame Y,Arora H,Hatem A,Patel SA,Lugnani F,Polascik TJ,Jones JS

    更新日期：2018-04-01 00:00:00

  • Clinical Outcomes in Patients With Metastatic Papillary Renal-Cell Carcinoma: A Multi-Institutional Study in Japan.

    abstract：BACKGROUND:Standard treatments have not been established in metastatic papillary renal-cell carcinoma (PRCC). We aimed to investigate treatment outcomes in patients with mPRCC. PATIENTS AND METHODS:This study included 51 patients who were diagnosed with PRCC at 14 institutions. Pathologic slides were reviewed by patho...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.clgc.2018.07.028

    authors： Ito K,Mikami S,Tatsugami K,Masumori N,Shinohara N,Kondo T,Nakanishi S,Nagashima Y,Eto M,Kamba T,Kuroda N,Tomita Y,Matsuyama H,Onishi T,Tsushima T,Nakazawa H,Oya M,Ozono S,Naito S,Asano T

    更新日期：2018-12-01 00:00:00

  • Development of a Novel Prognostic Risk Score for Predicting Complications of Penectomy in the Surgical Management of Penile Cancer.

    abstract：INTRODUCTION:Penectomy for PC is useful in staging, disease prognosis, and treatment. Limited studies have evaluated its surgical complications. We sought to assess these complications and determine predictive models to create a novel risk score for penectomy complications. PATIENTS AND METHODS:A retrospective review ...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2018.09.018

    authors： Velazquez N,Press B,Renson A,Wysock JS,Taneja S,Huang WC,Bjurlin MA

    更新日期：2019-02-01 00:00:00

  • Effect of perioperative blood transfusion on mortality for major urologic malignancies.

    abstract：INTRODUCTION:Patients who undergo surgical treatment for malignancy often receive perioperative blood transfusion (PBT). We examined the association between PBT and mortality in patients who received surgical treatment of prostate, bladder, and kidney cancer. MATERIALS AND METHODS:Using the Surveillance, Epidemiology,...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2014.12.006

    authors： Soubra A,Zabell JR,Adejoro O,Konety BR

    更新日期：2015-06-01 00:00:00

  • Role of Inflammation in the Perioperative Management of Urothelial Bladder Cancer With Squamous-Cell Features: Impact of Neutrophil-to-Lymphocyte Ratio on Outcomes and Response to Neoadjuvant Chemotherapy.

    abstract：BACKGROUND:Neutrophil-to-lymphocyte ratio (NLR) might reflect an increased neutrophilic inflammatory response, and urothelial tumors with squamous-cell features (SqD) have been linked to inflammation. We hypothesized that NLR could be prognostic in these patients. PATIENTS AND METHODS:In patients with SqD muscle-invas...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2017.01.024

    authors： Buisan O,Orsola A,Oliveira M,Martinez R,Etxaniz O,Areal J,Ibarz L

    更新日期：2017-08-01 00:00:00

  • Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors.

    abstract：BACKGROUND:Venous thromboembolism (VTE) is common in cancer patients, but there is limited data on patients with urothelial tract tumors (UTT). We previously identified several associative factors for increased VTE rates in patients with metastatic UTT. In this study, we assessed the frequency, associative factors, and...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2017.08.001

    authors： Ramos JD,Wingate JT,Gulati R,Plimack ER,Harshman LC,Powles T,Crabb SJ,Niegisch G,Bellmunt J,Ladoire S,De Giorgi U,Hussain S,Alva AS,Baniel J,Agarwal N,Rosenberg JE,Vaishampayan UN,Galsky MD,Yu EY,RISC Investigators.

    更新日期：2017-08-24 00:00:00

  • Baseline serum 25-hydroxyvitamin d levels in men undergoing radical prostatectomy: is there an association with adverse pathologic features?

    abstract：INTRODUCTION/BACKGROUND:The purpose of this study was to evaluate the prevalence of vitamin D (VitD) deficiency in men undergoing radical prostatectomy and determine whether an association exists between preoperative VitD levels and adverse pathologic features. PATIENTS AND METHODS:Patients scheduled to undergo radica...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2014.02.004

    authors： Berg WT,Shapiro EY,Rothberg MB,Bergman A,Scarberry K,Wambi C,Patel T,Badani KK

    更新日期：2014-10-01 00:00:00

  • Perinephric and Sinus Fat Invasion in Stage pT3a Tumors Managed by Partial Nephrectomy.

    abstract：INTRODUCTION:We evaluated the influence of perinephric fat invasion (PFI) compared with sinus fat invasion (SFI) on disease-free survival (DFS) and cancer-specific survival (CSS) after partial nephrectomy (PN) for stage pT3a renal cell carcinoma (RCC). MATERIALS AND METHODS:Data were recorded from the consecutive reco...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2017.07.019

    authors： Mouracade P,Dagenais J,Chavali JS,Kara O,Nelson RJ,Maurice MJ,Reese J,Rini BI,Kaouk JH

    更新日期：2018-10-01 00:00:00

  • Cost-effectiveness of Pembrolizumab versus Carboplatin-based Chemotherapy as First-line Treatment of PD-L1-positive Locally Advanced or Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Therapy in the United States.

    abstract：INTRODUCTION:Pembrolizumab has been approved in the United States (US) for the first-line treatment of patients with advanced or metastatic urothelial carcinoma, who are ineligible for cisplatin-containing chemotherapy and with tumors expressing programmed death-ligand 1 (PD-L1) (Combined Positive Score ≥ 10), or ineli...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2020.07.006

    authors： Hale O,Patterson K,Lai Y,Meng Y,Li H,Godwin JL,Homet Moreno B,Mamtani R

    更新日期：2020-07-16 00:00:00

  • Combined Angiogenesis and Proliferation Markers' Expressions as Long-Term Prognostic Factors in Renal Cell Cancer.

    abstract：OBJECTIVES:The aim of this study was to evaluate the expression of MIB-1, BCL-2, VEGFR3, and CD31 and their associations with long-term survival in patients with renal cell cancer (RCC). PATIENTS AND METHODS:This study consisted of 224 RCC patients who underwent radical nephrectomy from 1985 to 1995. Follow-up continu...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2015.12.014

    authors： Virman JP,Bono P,Luukkaala TH,Sunela KL,Kujala PM,Kellokumpu-Lehtinen PL

    更新日期：2016-08-01 00:00:00